International Women’s Day 2024: Investing in women to accelerate progress
This year on International Women’s Day, EDCTP joins the global health community in celebrating diversity and empowerment and underscores its commitment to investing in women and accelerating progress towards achieving gender equality in science.
EDCTP Career Development Fellow, Dr Margaret Japhet
Dr Margaret Oluwatoyin Japhet is an Associate Professor of Virology at the Department of Microbiology, Obafemi Awolowo University (OAU), Nigeria. She is an EDCTP and New York Academy of Science Fellow, being awarded different grants for viral studies by both organisations. Her research focus is on viral studies to solve indigenous and global human health problems.
“My EDCTP Fellowship allowed me to develop a rapid, sensitive and easy to perform equipment free rotavirus diagnostic kit using nanotechnology. Commercialisation and implementation of this test have the potential to enhance prompt and rapid diagnosis of rotavirus, leading to improved management of diarrhoea in children, which can ultimately reduce rotavirus diarrhoea morbidity and mortality in children. Additionally, this could lead to the development of other viral diagnostic kids and job creation.”
IMPROVE-2 and MAMAH
Malaria during pregnancy can cause serious maternal and newborn health issues, especially in women living with HIV. The World Health Organization (WHO) recommends daily doses of the antibiotic co-trimoxazole to prevent malaria in pregnant women living with HIV residing in areas with high malaria transmission. However, its efficacy in sub–Saharan Africa is threatened because malaria parasites are becoming increasingly resistant to the drug. Until now, no suitable alternative or additional preventative treatment has been identified for pregnant women living with HIV.
The results of IMPROVE-2 and MAMAH showed that the addition of the antimalarial drug dihydroartemisinin–piperaquine (DP) to daily co-trimoxazole substantially reduces the risk of malaria infection and disease in pregnant women on HIV treatment. These study results could lead to a much-needed policy change that could make a real difference in improving maternal and newborn health in Africa.
PROTECT project
The PROTECT project aims at developing the capacity to rapidly implement phase III/IV maternal vaccine clinical trials by addressing key gaps in the electronic health records in Kenya, Malawi, Mozambique, and Uganda. The focus will be on two vaccines for pregnant women that will protect their unborn infant from group B streptococcus and respiratory syncytial virus. Through the development of pregnancy registries, the project will enable healthcare professionals to monitor potential safety signals once the new vaccines are rolled-out. PROTECT will work closely with WHO, the African Medicines Agency and country stakeholders to co-develop pregnancy registries, surveillance systems, and maternal vaccination communications toolkits.